Edwards Lifesciences [EW] vs Abbott Laboratories [ABT] Detailed Stock Comparison
Edwards Lifesciences
NYSE
Loading...
Abbott Laboratories
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Edwards Lifesciences wins in 8 metrics, Abbott Laboratories wins in 11 metrics, with 0 ties. Abbott Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Edwards Lifesciences | Abbott Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 31.40 | 16.75 | Abbott Laboratories |
| Price-to-Book Ratio | 4.25 | 4.59 | Edwards Lifesciences |
| Debt-to-Equity Ratio | 6.62 | 26.50 | Edwards Lifesciences |
| PEG Ratio | -4.79 | 0.46 | Edwards Lifesciences |
| EV/EBITDA | 24.33 | 20.85 | Abbott Laboratories |
| Profit Margin (TTM) | 72.96% | 32.43% | Edwards Lifesciences |
| Operating Margin (TTM) | 28.12% | 19.73% | Edwards Lifesciences |
| EBITDA Margin (TTM) | 28.12% | 19.73% | Edwards Lifesciences |
| Return on Equity | 15.53% | 30.93% | Abbott Laboratories |
| Return on Assets (TTM) | 8.42% | 6.62% | Edwards Lifesciences |
| Free Cash Flow (TTM) | $259.90M | $6.35B | Abbott Laboratories |
| Dividend Yield | N/A | 1.28% | N/A |
| 1-Year Return | 17.04% | 18.07% | Abbott Laboratories |
| Price-to-Sales Ratio (TTM) | 7.88 | 5.39 | Abbott Laboratories |
| Enterprise Value | $42.36B | $238.75B | Abbott Laboratories |
| EV/Revenue Ratio | 7.45 | 5.54 | Abbott Laboratories |
| Gross Profit Margin (TTM) | 77.52% | 56.44% | Edwards Lifesciences |
| Revenue per Share (TTM) | $10 | $25 | Abbott Laboratories |
| Earnings per Share (Diluted) | $2.43 | $7.97 | Abbott Laboratories |
| Beta (Stock Volatility) | 1.07 | 0.70 | Abbott Laboratories |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Edwards Lifesciences vs Abbott Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Edwards Lifesciences | 0.45% | 1.83% | -6.26% | -0.48% | 6.38% | 5.59% |
| Abbott Laboratories | -0.36% | -0.24% | 1.16% | -0.84% | 0.80% | 17.23% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Edwards Lifesciences | 17.04% | -9.00% | -8.64% | 210.32% | 575.93% | 2,035.10% |
| Abbott Laboratories | 18.07% | 30.65% | 21.29% | 217.47% | 424.82% | 549.05% |
News Based Sentiment: Edwards Lifesciences vs Abbott Laboratories
Edwards Lifesciences
News based Sentiment: MIXED
October brought a mix of positive and negative developments for Edwards Lifesciences. While the stock received an upgrade and the healthcare sector outlook improved, earnings are expected to decline year-over-year. This creates a balanced investment narrative requiring close monitoring of upcoming earnings.
Abbott Laboratories
News based Sentiment: POSITIVE
Abbott Laboratories reported strong Q2 2025 earnings and raised its full-year guidance, leading to positive analyst upgrades and increased institutional investment. While the ongoing NEC litigation presents a risk, the overall narrative is positive, suggesting continued growth and profitability for the company.
Performance & Financial Health Analysis: Edwards Lifesciences vs Abbott Laboratories
| Metric | EW | ABT |
|---|---|---|
| Market Information | ||
| Market Cap | $45.70B | $231.60B |
| Market Cap Category | Large cap | Mega cap |
| 10 Day Avg. Volume | 4,916,428 | 6,299,450 |
| 90 Day Avg. Volume | 4,313,783 | 5,376,593 |
| Last Close | $76.65 | $132.99 |
| 52 Week Range | $64.01 - $83.00 | $110.86 - $141.23 |
| % from 52W High | -7.65% | -5.83% |
| All-Time High | $131.73 (Dec 27, 2021) | $142.60 (Dec 27, 2021) |
| % from All-Time High | -41.81% | -6.74% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.12% | 0.07% |
| Quarterly Earnings Growth | -0.09% | 0.37% |
| Financial Health | ||
| Profit Margin (TTM) | 0.73% | 0.32% |
| Operating Margin (TTM) | 0.28% | 0.20% |
| Return on Equity (TTM) | 0.16% | 0.31% |
| Debt to Equity (MRQ) | 6.62 | 26.50 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $17.94 | $29.05 |
| Cash per Share (MRQ) | $6.92 | $4.18 |
| Operating Cash Flow (TTM) | $794.90M | $9.04B |
| Levered Free Cash Flow (TTM) | $1.26B | $5.92B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.28% |
| Last 12-Month Dividend | N/A | $1.69 |
Valuation & Enterprise Metrics Analysis: Edwards Lifesciences vs Abbott Laboratories
| Metric | EW | ABT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 31.40 | 16.75 |
| Forward P/E | 31.15 | 25.87 |
| PEG Ratio | -4.79 | 0.46 |
| Price to Sales (TTM) | 7.88 | 5.39 |
| Price to Book (MRQ) | 4.25 | 4.59 |
| Market Capitalization | ||
| Market Capitalization | $45.70B | $231.60B |
| Enterprise Value | $42.36B | $238.75B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 7.45 | 5.54 |
| Enterprise to EBITDA | 24.33 | 20.85 |
| Risk & Other Metrics | ||
| Beta | 1.07 | 0.70 |
| Book Value per Share (MRQ) | $17.94 | $29.05 |
Financial Statements Comparison: Edwards Lifesciences vs Abbott Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | EW | ABT |
|---|---|---|
| Revenue/Sales | $1.41B | $10.36B |
| Cost of Goods Sold | $301.60M | $4.47B |
| Gross Profit | $1.11B | $5.89B |
| Research & Development | $254.60M | $716.00M |
| Operating Income (EBIT) | $409.90M | $1.69B |
| EBITDA | $461.60M | $2.66B |
| Pre-Tax Income | $433.90M | $1.78B |
| Income Tax | $70.30M | $453.00M |
| Net Income (Profit) | $356.40M | $1.33B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | EW | ABT |
|---|---|---|
| Cash & Equivalents | $3.14B | $6.53B |
| Total Current Assets | $6.21B | $23.15B |
| Total Current Liabilities | $1.39B | $13.00B |
| Long-Term Debt | $675.70M | $12.74B |
| Total Shareholders Equity | $10.19B | $49.06B |
| Retained Earnings | $13.53B | $47.72B |
| Property, Plant & Equipment | $1.80B | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | EW | ABT |
|---|---|---|
| Operating Cash Flow | $294.00M | $1.42B |
| Capital Expenditures | N/A | $-484.00M |
| Free Cash Flow | $224.40M | $933.00M |
| Debt Repayment | N/A | $-1.00B |
| Common Stock Repurchase | $-258.60M | $-280.00M |
Short Interest & Institutional Ownership Analysis
| Metric | EW | ABT |
|---|---|---|
| Shares Short | 7.26M | 18.07M |
| Short Ratio | 1.86 | 3.68 |
| Short % of Float | 0.01% | 0.01% |
| Average Daily Volume (10 Day) | 4,916,428 | 6,299,450 |
| Average Daily Volume (90 Day) | 4,313,783 | 5,376,593 |
| Shares Outstanding | 588.60M | 1.73B |
| Float Shares | 581.11M | 1.73B |
| % Held by Insiders | 0.01% | 0.01% |
| % Held by Institutions | 0.88% | 0.81% |
Dividend Analysis & Yield Comparison: Edwards Lifesciences vs Abbott Laboratories
| Metric | EW | ABT |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.69 |
| Last 12-Month Dividend Yield | N/A | 1.28% |
| 3-Year Avg Annual Dividend | N/A | $1.92 |
| 3-Year Avg Dividend Yield | N/A | 0.49% |
| 3-Year Total Dividends | N/A | $5.77 |
| Ex-Dividend Date | N/A | Jan 15, 2025 |